MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Talquetamab

  • Home
  • Talquetamab
Posted inHematology-Oncology news

Comprehensive Summary of Talquetamab Monotherapy and Combination Therapy in Relapsed or Refractory Multiple Myeloma

Posted by By MedXY 12/19/2025
Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.
Read More
Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma
Posted inHematology-Oncology news

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

Posted by By MedXY 10/14/2025
The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated patients.
Read More
  • Decoding Pancreatic Islet Single-Cell Transcriptomic Diversity Across Type 2 Diabetes Subtypes
  • Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Glucose Metabolism in Youths with Cystic Fibrosis: Insights from Continuous Glucose Monitoring
  • Approach to the Patient: Theranostics as Precision Medicine for Neuroendocrine Tumors
  • Charcot Neuro-Osteoarthropathy in Diabetes: High Risk of Hospitalization, Amputation, and Mortality Revealed by Regional Cohort Study
  • Gestational Diabetes Mellitus: Insights from 25 Years of Research on Early Risk, Prevention, and Long-Term Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top